371 related articles for article (PubMed ID: 19411762)
1. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
Song L; Asgharzadeh S; Salo J; Engell K; Wu HW; Sposto R; Ara T; Silverman AM; DeClerck YA; Seeger RC; Metelitsa LS
J Clin Invest; 2009 Jun; 119(6):1524-36. PubMed ID: 19411762
[TBL] [Abstract][Full Text] [Related]
2. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
3. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.
Tian G; Courtney AN; Jena B; Heczey A; Liu D; Marinova E; Guo L; Xu X; Torikai H; Mo Q; Dotti G; Cooper LJ; Metelitsa LS
J Clin Invest; 2016 Jun; 126(6):2341-55. PubMed ID: 27183388
[TBL] [Abstract][Full Text] [Related]
4. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
Liu D; Song L; Wei J; Courtney AN; Gao X; Marinova E; Guo L; Heczey A; Asgharzadeh S; Kim E; Dotti G; Metelitsa LS
J Clin Invest; 2012 Jun; 122(6):2221-33. PubMed ID: 22565311
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.
Metelitsa LS
Clin Immunol; 2011 Aug; 140(2):119-29. PubMed ID: 21095162
[TBL] [Abstract][Full Text] [Related]
6. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
7. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
8. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
[TBL] [Abstract][Full Text] [Related]
9. IL-21 Selectively Protects CD62L
Ngai H; Tian G; Courtney AN; Ravari SB; Guo L; Liu B; Jin J; Shen ET; Di Pierro EJ; Metelitsa LS
J Immunol; 2018 Oct; 201(7):2141-2153. PubMed ID: 30111631
[TBL] [Abstract][Full Text] [Related]
10. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.
Webb MW; Sun J; Sheard MA; Liu WY; Wu HW; Jackson JR; Malvar J; Sposto R; Daniel D; Seeger RC
Int J Cancer; 2018 Sep; 143(6):1483-1493. PubMed ID: 29665011
[TBL] [Abstract][Full Text] [Related]
11. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.
Liu D; Song L; Brawley VS; Robison N; Wei J; Gao X; Tian G; Margol A; Ahmed N; Asgharzadeh S; Metelitsa LS
Clin Immunol; 2013 Oct; 149(1):55-64. PubMed ID: 23891738
[TBL] [Abstract][Full Text] [Related]
12. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
Gerth E; Mattner J
Front Immunol; 2019; 10():1449. PubMed ID: 31293596
[TBL] [Abstract][Full Text] [Related]
13. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
[TBL] [Abstract][Full Text] [Related]
14. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Singh AK; Rhost S; Löfbom L; Cardell SL
Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
Teo WY; Elghetany MT; Shen J; Man TK; Li X; Chintagumpala M; Su JM; Dauser R; Whitehead W; Adesina AM; Lau CC
J Neurooncol; 2014 Nov; 120(2):293-301. PubMed ID: 25115738
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
[TBL] [Abstract][Full Text] [Related]
17. Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset.
Dasgupta S; Kumar V
Immunogenetics; 2016 Aug; 68(8):665-76. PubMed ID: 27405300
[TBL] [Abstract][Full Text] [Related]
18. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
19. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
[TBL] [Abstract][Full Text] [Related]
20. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
